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Abstract 
BACKGROUND: Osteosarcoma and chondrosarcoma, remain the most common primary bone tumours. 
Questions have been raised about the prognostic influence of HER-2 in bone sarcomas, but so far the results 
have been debatable. The her-2 expression is possibly a predictor of chemotherapy response.  
AIM: In this study, we investigated the extent of HER-2 expression in bone sarcomas, and attempted to correlate 
it with pertinent variables that will help to provide better treatment options, especially for metastatic ones. 
MATERIAL AND METHODS: Fifty-two cases of bone sarcomas (32 osteosarcoma cases and 20 
chondrosarcoma ones) were studied for HER-2 immunohistochemical expression then correlation with all 
available clinicopathologic features was done. 
RESULTS: Most of the osteosarcoma cases exhibited membranous staining (78.1%). Strong staining was 
observed (score 3+) in 34.4%; while 21.9% showed moderate staining (score 2+); and 21.9% displayed weak 
staining (score 1+), on the other hand, no staining was detected in 7 out of 32 cases (21.9%) (score 0). As 
regards chondrosarcoma, the absence of staining in all examined cases was noted. Immunohistochemical HER-2 
overexpression correlated significantly with osteosarcoma site with P value = 0.004, with variation relating HER-2 
intensity score to the site of osteosarcoma (P = 0.051). A statistically significant negative correlation was detected 
between HER-2 expression and the presence of metastasis at time of diagnosis (P = 0.006), A significant 
correlation was also found regarding HER-2 score and presence of metastasis with P value = 0.046 as more than 
half of cases with no metastasis at diagnosis (17/28 cases, 60.7%) showed positive intensity score. A statistically 
significant correlation was detected between HER-2 expression and patients’ age (P = 0.044). Also, HER-2 
expression significantly correlated to histopathological detection of fibrous tissue, with P value = 0.033. Higher 
scores of HER-2 expression were associated with a significantly better differentiation (P = 0.038) since detection 
of wide areas of osteoid were associated with higher HER-2 scores. 
CONCLUSION: Further research would still be needed to delineate HER-2 role being a new hope for therapeutic 
targeting in bone sarcoma patients, mainly osteosarcoma in contrast to chondrosarcoma that didn’t express HER-
2 at all. 
 
 
 
 
Introduction 
 
Osteosarcoma and chondrosarcoma, remain 
the most common primary bone tumours [1]. 
Osteosarcoma is a primary skeletal malignancy, 
signified by malignant spindle cells of mesenchymal 
origin with deposition of the immature osteoid matrix 
[2] [3]. Histologically, osteosarcoma subtypes can be 
separated into high and low-grades. Treatment of low-
grade tumours involves surgery alone and bears a 
favourable prognosis. High-grade osteosarcoma 
should be regarded as micrometastatic at diagnosis 
and thereupon treated with both surgery and systemic 
chemotherapy [4].  
Surgery and chemotherapy are relatively 
successful treatment modalities for localised disease, 
yet metastatic disease continues to be a challenging 
issue [5]. Nearly 15-20% of patients have evidence of 
metastases at diagnosis. Moreover, patients having 
the metastatic disease have a very poor prognosis, 
with approximately only 20-30% of them being long-
term survivors, as compared to 65-70% of patients 
having localised disease [6]. The ability to stratify 
patients at diagnosis is imperative to identify 
prognostic factors, to select patients who might benefit 
from more intensive forms of therapy. Recognition of 
select malignant cellular features could make up the 
keystone of targeted therapy interferences [7].  
Concerning chondrosarcoma, it may arise de 
novo and hence called primary, whereas those 
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developing on top of preexisting benign cartilaginous 
tumours are itemised as secondary. 
Chondrosarcomas being heterogeneous, can be 
categorised by anatomic location into central or 
peripheral. Besides conventional chondrosarcoma 
that exhibits hyaline cartilage differentiation, other 
types include dedifferentiated, mesenchymal, and 
clear cell ones [8].  
Chondrosarcoma is typically considered to be 
resistant to conventional chemotherapy and 
radiotherapy [9]. Accordingly, surgical resection has 
been the primary form of treatment. Thus, 
identification of prognostic factors is of dire necessity, 
not only to predict patients’ outcome but also to shape 
decisions as regards treatment. Novel therapeutic 
approaches have been appraised in an experimental 
study [10].  Human epidermal growth factor receptor 2 
(HER-2) has been viewed as a protein of potential 
prognostic importance in addition to being a 
therapeutic target. Additionally, it is fundamentally 
involved in the pathogenesis of several human 
cancers. Through some pathways, it regulates cell 
growth, survival, cellular proliferation and 
differentiation [7] [11].  
Questions have been raised about the 
prognostic influence of Her-2 in bone sarcomas, but 
so far the results have been debatable. Meanwhile, 
the HER-2 expression is possibly a predictor of 
chemotherapy response [12] [13]. In this study, we 
investigated the extent of HER-2 expression in bone 
sarcomas and attempted to correlate it with pertinent 
variables that will help to provide better treatment 
options, especially for metastatic ones. 
 
 
Material and Methods 
 
This retrospective study was conducted on 52 
cases of bone sarcomas (32 osteosarcoma cases and 
20 chondrosarcoma ones). Formalin-fixed paraffin-
embedded tumour (FFPE) blocks of patients, 
diagnosed as osteosarcoma or chondrosarcoma were 
collected from Pathology Department, Kasr Alainy 
Hospital, Faculty of Medicine, Cairo University, after 
receiving approval from the institutional research 
ethics committee. 
Four µm sections from each submitted tumour 
paraffin block were stained with hematoxylin and 
eosin, to assess pertinent histologic findings. 
Exclusion criteria for tumour blocks included scanty 
tumour tissue, poor fixation and overt necrosis. Serial 
sections (4 µm) were prepared and float-mounted on 
adhesive-coated glass slides for HER-2 staining. 
Primary antibodies included rabbit antihuman c-erbB2 
(HER-2) oncoprotein antibody (DAKO, Dako 
Corporation, Carpinteria, CA, USA) at 1:200 dilution 
for HER-2. The DAKO Envision system (DAKO 
Envision labelled polymer, peroxidase) was used as 
the detection system for HER-2. For all cases, a 
negative control was the adjacent non-tumorous part 
of the specimen and the positive control was a known 
HER2/neu-overexpressing breast carcinoma.  
Hematoxylin and eosin stained sections were 
evaluated by light microscopy along with Her-2 
immunohistochemically stained slides were then 
scored. To determine the score of HER-2 expression, 
both the membrane and cytoplasmic staining patterns 
were estimated, and its intensity was scored on a 
scale of 0 to 3+. A reaction in > 20% of cells in the 
membrane (focal/linear) or cytoplasm, with an 
intensity score of 2 or greater, was considered 
positive, provided that the staining was limited to the 
tumour cells and did not represent background or 
artefact [14].  
Clinical data were retrieved from patients’ 
files, including the age, gender, site of a tumour, and 
metastasis presentation. Histopathologic features 
were assessed as regards type, grade, necrosis, and 
matrix differentiation. Her-2 immunohistochemical 
results were recorded. Findings were then tabulated. 
Collected data was documented using the 
Statistical Package for the Social Sciences (SPSS) 
version 22.0 (IBM Corp., Armonk, NY, USA). 
Statistical analysis was done using descriptive 
statistics. Results were expressed as percentages, 
frequencies, and mean ± S.D. correlations were 
determined using the Chi-square 2 test. A p value of 
less than 0.05 represented significance. 
 
 
Results 
 
Fifty two bone sarcoma cases were enrolled 
in this study. Median age was 40 years, with 27 
(51.9%) males and 25 (48.1%) females. Patients 
ranged in age from 10 to 86 years, with a mean of 
40.4 ± 19.888 years. The osteosarcoma series 
included 32 cases ranged from 10 to 86 years, with a 
mean of 32.38 ± 16.590 years, while chondrosarcoma 
cases included 20 cases with a range from 25 to 85 
years and a mean of 53.25 ± 14.682 years. 
All of the 52 cases were evaluated for HER-2 
expression by immunohistochemical staining. 
Regarding cases of osteosarcoma, the vast majority 
of specimens exhibited membranous staining (either 
complete or not) (25 cases out of 32, 78.1%). A strong 
staining was observed in > 20% of cells in the 
membrane (focal/linear) or cytoplasm (score 3+, 
strongly positive cases) in 11 out of 32 cases (34.4%); 
while 7 cases out of 32 (21.9%) showed moderate 
staining (score 2+, equivocal or weakly positive); and 
7 cases (21.9%) displayed weak staining in more than 
20% of the tumor cells (score 1+, negative), on the 
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other hand, no staining was detected in 7 out of 32 
cases (21.9%) (score 0, negative) (Figures 1, 2, and 
3). 
 
Figure 1: HER-2 positive immunohistochemical staining where the 
neoplastic cells of osteosarcoma showed staining in part of their 
membrane (low power) 
 
As regards chondrosarcoma, the degree of 
immunohistochemical expression of HER-2 was 
similar in all cases given the absence of staining in all 
of the 20 examined cases (Figure 4). 
 
Figure 2: positive both cytoplasmic and membranous staining of 
HER-2 in a case of osteosarcoma (high power) 
Clinicopathologic characteristics of cases and 
the results of HER-2 immunostaining are listed in 
Tables 1, 2, and 3. 
 
Figure 3: cytoplasmic staining of HER-2 without membrane staining 
in osteosarcoma case (high power) 
 
Figure 4: Chondrosarcoma with negative her-2 staining (high 
power) 
 
Immunohistochemical HER-2 overexpression 
correlated significantly with osteosarcoma site with P 
value = 0.004, where 43.7% of the cases showed 
positive membranous staining, located in an extremity. 
Also, variation was found relating HER-2 intensity 
score to the site of osteosarcoma, and this difference 
nearly reached statistical significance, with P = 0.051. 
Table 1: HER-2 immunohistochemical expression in correlation 
to osteosarcoma patients’ clinicopathologic characteristics 
 
HER- 2 membranous staining 
Total 
P 
value 
No 
membranous 
staining 
Positive for 
any 
membranous 
staining 
Gender 
Female 1 (3.1%) 12 (37.5%) 13 (40.6%) 
0.108 
Male 6 (18.8%) 13 (40.6%) 19 (59.4%) 
Site 
Axial 3 (9.4%) 11 (34.4%) 14 (43.8%) 
0.004 
Extremity 4 (12.5%) 14 (43.7%) 18 (56.2%) 
Presence of 
metastasis at 
the time of 
diagnosis 
 
No 
metastasis 
4 (12.5%) 24 (75.0%) 28 (87.5%) 
0.006 
+ve for 
metastasis 
3 (9.4%) 1 (3.1%) 4 (12.5%) 
Age group 
Less than 
20 yr 
0 (0.0%) 10 (31.3%) 10 (31.3%) 
0.044 
20 yr or 
more 
7 (21.9%) 15 (46.9%) 22 (68.8%) 
Grade 
High 7 (21.9%) 19 (59.4%) 26 (81.3%) 
0.150 
Low 0 (0.0%) 6 (18.8%) 6 (18.8%) 
Presence of 
necrosis 
Absent  2 (6.3%) 12 (37.5%) 14 (43.8%) 
0.360 
Present 5 (15.6%) 13 (40.6%) 18 (56.3%) 
Presence of 
cartilage  
Absent  5 (15.6%) 14 (43.8%) 19 (59.4%) 
0.463 
Present 2 (6.3%) 11 (34.4%) 13 (40.6%) 
Presence of 
fibrous tissue 
Absent  6 (18.8%) 10 (31.3%) 16 (50.0%) 
0.033 
Present 1 (3.1%) 15 (46.9%) 16 (50.0%) 
Osteoid tissue 
detection 
Focal 7 (21.9%) 19 (59.4%) 26 (81.3%) 
0.150 
Wide 0 (0.0%) 6 (18.8%) 6 (18.8%) 
 
A statistically significant negative correlation 
was detected between HER-2 immunohistochemical 
expression and the presence of metastasis at the time 
of diagnosis (P = 0.006), as 85.7%, (24/28 cases) with 
the absence of metastatic deposits at the time of 
diagnosis showed HER-2 membranous staining. A 
significant correlation was also found regarding HER-
2 score and presence of metastasis with P value = 
0.046 as more than half of cases with no metastasis 
at diagnosis (17/28 cases, 60.7%) showed positive 
intensity score. 
A statistically significant correlation was 
detected between levels of HER-2 
immunohistochemical expression and patients’ age (P 
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= 0.044) where HER-2 was expressed more in the 
younger age group (˂20 years) in which all cases 
(10/10) showed membranous staining. 
Table 2: Intensity scoring for HER-2 expression in correlation 
to clinicopathologic data of osteosarcoma cases 
 
HER-2 score 
Total 
P 
value 0 1+ 2+ 3+ 
Gender 
Female 1 (3.1%) 3 (9.4%) 4 (12.5%) 5 (15.6%) 13 (40.6%) 
0.403 
Male 6 (18.8%) 4 (12.5%) 3 (9.4%) 6 (18.8%) 19 (59.4%) 
Site 
Axial 3 (9.4%) 3 (9.4%) 2 (6.3%) 6 (18.7%) 14 (43.7%) 
0.051 
Extremity 4 (12.5%) 4 (12.5%) 5 (15.6%) 5 (15.6%) 18 (56.3%) 
Presence of 
metastasis at 
time of 
diagnosis 
No 
metastasis 
4 (12.5)% 7 (21.9%) 7 (21.9%) 10 (31.3%) 28 (87.5%) 
0.046 
+ve for 
metastasis 
3 (9.4%) 0 (0.0%) 0 (0.0%) 1 (3.1%) 4 (12.5%) 
Age group 
Less than 
20 yrs 
0 (0.0%) 3 (9.4%) 2 (6.3%) 5 (15.6%) 10 (31.3%) 
0.197 
20 yrs or 
more 
7 (21.9%) 4 (12.5%) 5 (15.6%) 6 (18.8%) 22 (68.8%) 
Grade 
High 7 (21.9%) 4 (12.5%) 5 (15.6%) 10 (31.3%) 26 (81.3%) 
0.145 
Low 0 (0.0%) 3 (9.4%) 2 (6.3%) 1 (3.1%) 6 (18.8%) 
Presence of 
necrosis 
Absent 2 (6.3%) 3 (9.4%) 4 (12.5%) 5 (15.6%) 14 (43.8%) 
0.758 
Present 5 (15.6%) 4 (12.5%) 3 (9.4%) 6 (18.8%) 18 (56.3%) 
Presence of 
cartilage 
Absent 5 (15.6%) 4 (12.5%) 4 (12.5%) 6 (18.8%) 19 (59.4%) 
0.906 
Present 2 (6.3%) 3 (9.4%) 3 (9.4%) 5 (15.6%) 13 (40.6%) 
Presence of 
Fibrous 
tissue 
Absent 6 (18.8%) 3 (9.4%) 3 (9.4%) 4 (12.5%) 16 (50.0%) 
0.197 
present 1 (3.1%) 4 (12.5%) 4 (12.5%) 7 (21.9%) 16 (50.0%) 
Osteoid 
tissue 
detection 
Focal 7 (21.9%) 4 (12.5%) 7 (21.9%) 8 (25.0%) 26 (81.3%) 
0.038 
Wide 0 (0.0%) 3 (9.4%) 0 (0.0%) 3 (9.4%) 6 (18.8%) 
 
HER-2 immunohistochemical expression 
significantly correlated to histopathological detection 
of fibrous tissue, with P value = 0.033. Osteosarcoma 
cases showing fibrosis expressed HER-2 more 
frequently than those without a fibrous tissue. 
Table 3: HER-2 immunohistochemical expression in correlation 
to chondrosarcoma patients’ clinicopathologic characteristics 
 HER-2 membranous staining 
No membranous 
staining at all 
Positive for 
membranous staining 
Count % Count % 
Age group Less than 52 yrs 10 50.0 0 0 
52 yrs or more 10 50.0 0 0 
Gender  Female 12 60.0 0 0 
Male 8 40.0 0 0 
Site Axial 10 50.0 0 0 
Extremity  10 50.0 0 0 
Biopsy Excision  13 65.0 0 0 
Incision  7 35.0 0 0 
Grade I 16 80.0 0 0 
II 4 20.0 0 0 
Cartilage Focal 6 30.0 0 0 
Wide 14 70.0 0 0 
Myxoid No present 12 60.0 0 0 
Present  8 40.0 0 0 
Necrosis No 19 95.0 0 0 
Wide areas 1 5.0 0 0 
Histological 
type 
Chondrosarcoma, 
conventional 
14 70.0 0 0 
Mesenchymal, 
Chondrosarcoma 
1 5.0 0 0 
Myxoid Chondrosarcoma 5 25.0 0 0 
 
Higher scores of HER-2 expression were 
associated with a significantly better differentiation (P 
= 0.038) since detection of wide areas of osteoid were 
associated with higher HER-2 scores. 
There were no statistically significant 
differences in the other clinicopathologic features as 
patient gender, tumour grade, the presence of 
necrotic foci or cartilaginous areas between 
osteosarcomas cases expressing or lacking HER-2. 
Overexpression of HER-2 has not noted in 
any of the chondrosarcomas studied cases with 
similar absence of expression in all cases regardless 
of diverse clinicopathologic characters. 
Discussion 
 
Bone tumours’, mainly osteosarcoma and 
chondrosarcoma prognostic factors at diagnosis other 
than clinical stage have not been identified, and this is 
the only method that determines prognosis and 
therapy of patients. Therefore, there is a critical need 
for feasible prognostic and possibly therapeutic 
methods. 
HER-2 has been applied as being a promising 
marker for targeted biological therapy. The 
development of trastuzumab, a humanised 
monoclonal antibody that binds specifically to HER’s-2 
prompted an opening to make use of this targeted 
therapy [15]. Thus, clinically the demand for HER-2 
assessment is rapidly rising. 
 The HER-2 immunohistochemical expression 
has been detected in tissues derived from all three 
germ layers. Its expression has been observed in fetal 
tissue as well. In embryos, the expression of HER-2 
was observed in the placenta, genitourinary tract 
epithelium, gastrointestinal tissue, pulmonary tract 
and the adrenal medulla. In contrast, HER-2 was not 
detected in liver, nervous tissue including brain, 
striated and smooth muscle, endothelium or 
fibroblasts of the embryo [16]. Adult tissue expression 
levels are lower than those in the early stages of 
development. These expression patterns ascertain the 
prospect for the involvement of HER-2 in a range of 
human neoplasms. The HER-2 expression has been 
recognised in some tumour types mainly breast, 
gastric, oesophageal, pancreatic, and many others. 
Even though there are agreement about antibodies 
and tyrosine kinase inhibitors targeting HER-2 in the 
breast, gastric and oesophagal adenocarcinomas, still 
there are other evident prospects in other tumour 
types [17]. 
In this study, we examined HER-2 expression 
in the commonest primary malignant bone tumours 
namely osteo and chondrosarcomas, 
immunohistochemically, as being a practical and cost-
effective method available in most laboratories. 
Accordingly, immunohistochemistry is the most 
widespread method of HER-2 assessment.  
In the current study, HER-2 has been 
identified as an important possible prognostic, 
therapeutic factor in osteosarcomas. First, we 
illustrated the immunohistochemical expression of 
HER-2 in osteosarcomas, where 78.1% of the studied 
cases (25/32) exhibited membranous staining 
(whether complete or not). Our results were higher 
than those of Gorlick et al., [18] who demonstrated 
somewhat high levels of HER-2 expression in 42.6% 
of their cases and Japanese investigators [19] who 
reported HER-2 overexpression in 42% of their 
patients. Moreover, Ma et al., [20] assured that 60.3% 
of their samples were HER-2 positive (ranging from 
low- to high-positivity). Additionally, Ebb et al., [21] 
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reported that around half of their cases showed 
positive HER-2 membranous staining. This high 
expression incidence was greater than what was 
previously demonstrated by Thomas et al., [22] and 
Kilpatrick [23] who both reported lack of membranous 
HER-2 immunoreactivity in their samples. 
Moreover, Zhou et al., [24] revealed that the 
vast majority of their cases exhibited immunopositivity 
with focal to diffuse cytoplasmic reactivity yet without 
any membranous staining. This inconsistency could 
be explained by geographic and genetic variability 
between patients, sample size, differences in 
immunohistochemical processing (either decalcified or 
not and the duration of fixation), and variability in 
scoring methods with different thresholds or tumour 
heterogeneity [25]. Furthermore, the results are also 
contingent on the antibody used where Press et al. 
evaluated a panel of 28 antibodies (7 polyclonal and 
21 monoclonal antibodies) on 187 cases previously 
shown to be HER-2 positive and demonstrated that 
the ability to detect HER-2 positive cells varied vastly 
from 6% to 82% [26]. 
In this research work, overexpression of HER-
2 correlated significantly with the presence of 
osteosarcoma in an extremity rather than an axial site 
with P value = 0.004, also variation was noted relating 
the HER-2 intensity score to the osteosarcoma site, 
and this difference nearly reached statistical 
significance, with P value = 0.051. Also, a significant 
correlation was detected between the levels of HER-2 
immunohistochemical expression and the patients’ 
age (P = 0.044) where it was expressed more in the 
younger age group. Besides, a significant negative 
correlation was detected between HER-2 
membranous immunohistochemical expression and 
absence of metastasis at the time of diagnosis (P = 
0.006). This significant correlation was also attained 
as regards HER-2 score and the presence of 
metastasis with P value = 0.046, as more than half of 
cases which failed to show metastasis at diagnosis 
(60.7%, 17/28 cases) revealed positive intensity 
score. These findings support the belief that HER-2 
level of expression may have a role in the early 
development of osteosarcoma, and it may act as a 
marker of good prognostic significance as it is down-
regulated in tumors with metastatic deposits at the 
time of diagnosis. This is in agreement with the 
conclusions drawn by some previous investigators as 
Akatsuka and his colleagues [27], who demonstrated 
low levels of expression of HER-2 in metastatic 
lesions relative to the primary tumour. The majority of 
the earlier research studies demonstrated the poor 
prognostic effect of HER-2 overexpression mainly in 
the presence of metastasis as proclaimed by Gorlick 
et al., Ma et al., Onda et al., and Li et al., [18] [19] [20] 
[28] as they showed overexpression of HER-2 with 
poor prognostic factors mainly the presence of 
metastasis. 
In this work, we reported that osteosarcomas 
with considerable fibrosis expressed HER-2 more 
frequently than osteosarcomas without, achieving a 
statistically significant relationship with a P value of 
0.033. Also, higher scores of HER-2 
immunohistochemical expression were associated 
with significantly better differentiation (P = 0.038) 
since detection of wide areas of osteoid were 
associated with higher HER-2 scores. Similar patterns 
of expression were also observed in the study by 
Zhou et al., [24] where they reported cytoplasmic 
staining more in undifferentiated spindle cells, while 
both membranous and cytoplasmic staining was 
detected in differentiated, malignant-appearing 
chondroblastic foci. 
Regarding chondrosarcoma, the level of 
immunohistochemical expression of HER-2 was 
similar in all cases as we didn’t find membranous 
staining in any of the examined cases. Our findings 
were just identical to those reported by Nelson et al. 
and Park et al., [17] [29] who couldn’t detect 
immunohistochemical staining of HER-2 in their 
chondrosarcoma cases. Therefore, it is unlikely that 
targeted therapy against HER-2 overexpression could 
be used effectively in the treatment of such miserable 
patients also experiencing well-known resistance to 
most chemotherapeutic regimens.  
In conclusion, Her-2 has expressed in bone 
sarcomas specifically osteosarcoma, and it is 
probably related to tumour prognosis and outcome. It 
may act as a marker of good prognostic significance 
as it is down-regulated in tumours with metastatic 
deposits at time of diagnosis. 
Further clinicopathologic research work would 
still be needed to delineate its role being a new hope 
for therapeutic targeting in bone sarcoma patients, 
mainly osteosarcoma in contrast to chondrosarcoma 
that didn’t express HER-2 at all. 
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